InterStim Therapy System, Verify Evaluation System
Medtronic Neuromodulation · Decision date Oct 9, 2026
What did the FDA decide?
The FDA record for P080025/S353 describes a 30-day notice submitted by Medtronic Neuromodulation covering a process change attributed to a manufacturer, sterilizer, packager or supplier. The stated purpose is approval for the introduction of a second Medium Rate (MR) Header's manufacturing line, designated MR Line 2, and to make inspection updates to the MR Headers Line currently in production at Medtronic Energy and Components Center (MECC), Brooklyn Center, MN.
The product code QON places this under an implanted electrical device intended for treatment of fecal incontinence, with specialties listed as gastroenterology and urology. The supplement number establishes a relationship to the original PMA P080025, but this notice is a manufacturing change, not a new approval of the entire InterStim Therapy System or Verify Evaluation System. The record does not report clinical data, safety or effectiveness findings, or line-level technical specifications, so those details are absent rather than established by this entry.
FDA approval order statement
approval for the introduction of a second Medium Rate (MR) Headers manufacturing line (MR Line 2) and to make inspection updates to the MR Headers Line that is currently in production at Medtronic Energy and Components Center (MECC), Brooklyn Center, MN.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 9, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P080025/S353
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Neuromodulation
- Product code
- QON
- Decision code
- OK30
- Decision date
- Oct 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implanted electrical device intended for treatment of fecal incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- QON
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P080025. Subsequent supplements may change the device or its indications.
FDA decision timeline
P080025 · Original PMA
MEDTRONIC INTERSTIM SACRAL NERVE STIMULATION THERAPY SYSTEM
P080025/S353 received
Application receipt date recorded by FDA.
P080025/S352 · Related supplement
InterStim Therapy System, Verify Evaluation System
P080025/S351 · Related supplement
lnterStim Therapy System, Verify Evaluation System
P080025/S353 · FDA decision
30-Day Notice
P080025/S354 · Related supplement
InterStim Therapy System, Verify Evaluation System (SNS Bowel Neurostimulator 97800), (SNS Bowel Neurostimulators Impl
Timeline entries are records held by MedtechLedger for P080025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P080025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA approval | Mar 14, 2011 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Ms Rcw225, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P080025/S353
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


